SCA
VIRX

SAC Capital Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

SAC Capital Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-2,395
Closed -$3.32M – 1095
2014
Q1 		$3.32M Buy
+2,395
New +$2.78M 0.02% 644

Other funds holding VIRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SAC Capital Advisors's VIRX Position: Q2 2014 in Review

SAC Capital Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2014, closing a stake of 2,395 shares — an estimated $3.32M sold.

SAC Capital Advisors first reported a position in VIRX in Q1 2014 and held it in 1 quarter. The position peaked at $3.32M in Q1 2014. 102 funds tracked by Wall St. Rank hold VIRX as of Q2 2014.

  • SAC Capital Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2014 after selling out during the quarter.
  • SAC Capital Advisors sold 2,395 Viracta Therapeutics, Inc. Common Stock shares in Q2 2014, an estimated $3.32M.
  • SAC Capital Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 1 quarter.
  • SAC Capital Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $3.32M in Q1 2014.
  • 102 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2014.

Based on SAC Capital Advisors's 13F filing for Q2 2014.